Literature DB >> 12518325

Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats.

Klaus Jung1, Hans-Willi Krell, Bernhard Ortel, Tayyaba Hasan, Andreas Römer, Dietmar Schnorr, Stefan A Loening, Michael Lein.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) play an important role in invasion and metastatic spread of cancer cells. The objective of this study was to assess MMPs in plasma of Dunning tumor rats as indicators of the progression of prostate cancer and follow-up parameters after treatment.
METHODS: Prostate cancer was induced in male Copenhagen rats by either subcutaneous or orthotopic implantation of R3327-MatLyLu cells. During the development of the tumor, plasma MMP-2, and MMP-9 were measured by gelatin-substrate zymography and Western blot technique with densitometry in untreated animals, rats treated with laser-induced hyperthermia, or with the new synthetic MMP inhibitor RO 28-2653.
RESULTS: Normal prostatic tissue of the Copenhagen rats predominantly expressed proMMP-2 but not proMMP-9 whereas MMP-9 was only found in cancerous tissue. Elevated plasma MMP-9 values were demonstrated in rats with subcutaneous or orthotopic tumors. Animals with tumors and treated with the MMP inhibitor RO 28-2653 had both a lower tumor volume and a lower plasma MMP-9 concentration compared with controls.
CONCLUSIONS: The determination of plasma MMP-9 in Dunning tumor rats is a useful tool to monitor the progression of prostate cancer and to assess the efficacy of drugs like MMP inhibitors or other treatment protocols. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12518325     DOI: 10.1002/pros.10183

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Potential of fluorescent metalloproteinase substrates for cancer detection.

Authors:  Roopali Roy; David Zurakowski; Susan Pories; Marcia L Moss; Marsha A Moses
Journal:  Clin Biochem       Date:  2011-10-06       Impact factor: 3.281

2.  Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

Authors:  Stefan Lorenzl; Noel Calingasan; Lichuan Yang; David S Albers; Shuei Shugama; Jason Gregorio; H W Krell; Jason Chirichigno; Tong Joh; M Flint Beal
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

3.  Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.

Authors:  Roopali Roy; Gwendolyn Louis; Kevin R Loughlin; Dmitri Wiederschain; Susan M Kilroy; Carolyn C Lamb; David Zurakowski; Marsha A Moses
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

4.  Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis.

Authors:  Sai Murali Krishna Pulukuri; Jasti S Rao
Journal:  Int J Oncol       Date:  2008-04       Impact factor: 5.650

Review 5.  The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.

Authors:  Marley J Binder; Alister C Ward
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.